<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02317562</url>
  </required_header>
  <id_info>
    <org_study_id>I10E-1306</org_study_id>
    <nct_id>NCT02317562</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302</brief_title>
  <acronym>PRISM2</acronym>
  <official_title>International, Multicentre, Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Extension of PRISM Study I10E-1302&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoire français de Fractionnement et de Biotechnologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoire français de Fractionnement et de Biotechnologies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:

      To assess the efficacy of I10E administered at a reduced maintenance dose in sustaining CIDP
      response after an initial 6-month treatment in PRISM study. (I10E-1302).

      Secondary objective:

      To assess the safety of I10E in this patient population.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor's decision
  </why_stopped>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">July 28, 2017</completion_date>
  <primary_completion_date type="Actual">July 28, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy endpoint : Responder rate at end of study (EOS) visit</measure>
    <time_frame>48 weeks after first treatment administration</time_frame>
    <description>Responder Rate at EOS visit. Responders are defined as patients with either:
No change or decrease in the adjusted INCAT disability score and without any change in CIDP treatment between baseline and EOS visit.
or An increase by 1 point in the adjusted INCAT disability score without requirement of any change in CIDP treatment between baseline and EOS visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adjusted INCAT disability score</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes from baseline to 24 weeks (Visit V9) and EOS visit in the adjusted INCAT disability score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate at 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to relapse</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grip strength</measure>
    <time_frame>48 weeks</time_frame>
    <description>changes from baseline to 24 weeks (Visit V9) and EOS visit in Grip strength</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rasch-built Overall Disability Scale (R-ODS)</measure>
    <time_frame>48 weeks</time_frame>
    <description>changes from baseline to 24 weeks (Visit V9) and EOS visit in Rasch-built Overall Disability Scale (R-ODS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical Research Council (MRC) sum score</measure>
    <time_frame>48 weeks</time_frame>
    <description>changes from baseline to 24 weeks (Visit V9) and EOS visit in Medical Research Council (MRC) sum score</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Chronic Inflammatory Demyelinating Polyradiculoneuropathy</condition>
  <arm_group>
    <arm_group_label>I10E Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>I10E</intervention_name>
    <description>Patients who met all eligibility criteria will receive 0.5 g/kg of IMP every 3 weeks during 45 weeks.</description>
    <arm_group_label>I10E Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patient aged 18 years or more.

          2. Responder patient who have completed the last visit of PRISM I10E-1302 study defined
             as a patient with a decrease ≥1 point in the adjusted INCAT disability score between
             baseline and the end-of-study (EOS) visit of PRISM I10E-1302 study.

          3. Covered by national healthcare insurance system as required by local regulations.

          4. Written informed consent obtained prior to any study-related procedures.

        Exclusion Criteria:

          1. History of severe allergic reaction or serious adverse reaction to any Ig.

          2. Known hypersensitivity to human Ig or to any of the excipients of I10E (glycine and
             polysorbate 80).

          3. History of cardiac insufficiency (New York Heart Association (NYHA) III/IV),
             uncontrolled cardiac arrhythmia, unstable ischemic heart disease, or uncontrolled
             hypertension.

          4. History of venous thromboembolic disease, myocardial infarction or cerebrovascular
             accident.

          5. Risk factor for blood hyperviscosity such as cryoglobulinemia or haematological
             malignancy with monoclonal gammopathy.

          6. Body mass index (BMI) ≥40 kg/m².

          7. Glomerular filtration rate &lt;80 mL/min/1.73m² measured according to the Modified Diet
             Renal Disease (MDRD) calculation.

          8. Any other ongoing disease that may cause chronic peripheral neuropathy, such as toxin
             exposure, dietary deficiency, uncontrolled diabetes, hyperthyroidism, cancer, systemic
             lupus erythematosus or other connective tissue diseases, infection with HIV, Hepatitis
             B Virus (HBV) or Hepatitis C Virus (HCV), Lyme disease, multiple myeloma,
             Waldenström's macroglobulinaemia, amyloidosis, and hereditary neuropathy.

          9. Woman with positive results on a urine pregnancy test or breastfeeding woman or woman
             of childbearing potential without an effective contraception.

         10. Any other serious medical condition that would interfere with the clinical assessment
             of CIDP or use of I10E or prevent the patient from complying with the protocol
             requirements.

         11. Increasing dosage or introduction of a systemic corticosteroids therapy within the
             last 3 months prior to screening, at a dose higher than 10 mg daily prednisolone or
             equivalent. Topical corticosteroids are permitted.

         12. Treatment within 12 months prior to screening with immunomodulatory or
             immunosuppressant agents (including but not limited to cyclophosphamide, cyclosporine,
             interferon-α, interferon-β1a, anti-CD20, alemtuzumab, aziathioprine, etanercept,
             mycophenolate mofetil and methotrexate) or haemopoetic stem cell transplantation.

         13. Plasma exchange, blood products or derivatives administered within the last 3 months
             prior to screening.

         14. Anticipated poor compliance of patient with study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo NOBILE-ORAZIO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Instituto Clinico Humanitas, Milano, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Bordeaux - Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital général du CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - Hôpital l'Archet</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU paris - Hôpital Pitié salpétrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Saint Etienne - Hôpital Nord</name>
      <address>
        <city>Saint Etienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRRCS Azienda Ospedaliera Universitaria</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Instituto Clinico Humanitas</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRRCS Istutito Nazionale Neurologico Besta</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele IRCCS</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria di Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del sacro Cuore</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria san Giovanni</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la santa creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Seville</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario i Politècnico La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tunisia Hôpital Razi</name>
      <address>
        <city>La Manouba</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Fattouma Bourguiba</name>
      <address>
        <city>Monastir</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Habib Bourguiba</name>
      <address>
        <city>Sfax</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Sahloul</name>
      <address>
        <city>Sousse</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Militaire de Tunis</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara university medical school Neurology</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe University medical School Neurology</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uludag University Medical School Neurology</name>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>istanbul University Cerrahpasa Medical School Neurology</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marmara Universitesi Egitim Ve Arastirma Hastanesi</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southhampton general Hospital</name>
      <address>
        <city>Southhampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Straffordshire</name>
      <address>
        <city>Straffordshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Tunisia</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2014</study_first_submitted>
  <study_first_submitted_qc>December 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2014</study_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral neuropathy</keyword>
  <keyword>Disimmune disease</keyword>
  <keyword>Neurology chronic disease</keyword>
  <keyword>Rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyradiculoneuropathy</mesh_term>
    <mesh_term>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

